BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260317
DTEND;VALUE=DATE:20260320
DTSTAMP:20260515T002510
CREATED:20251125T102350Z
LAST-MODIFIED:20251125T102350Z
UID:42483-1773705600-1773964799@www.pharmajournalist.com
SUMMARY:5th Annual Novel Conjugates Summit
DESCRIPTION:Novel conjugates have become one of the most competitive and rapidly evolving areas in the precision oncology landscape. Companies are looking beyond traditional ADCs towards novel mechanism of action payloads and differentiated targeting formats for overcoming drug resistance\, improved therapeutic windows and to make an impact in cancers which don’t respond to traditional ADCs\, as well as the exploration of non-oncology indications. \nThe 5th Novel Conjugates Summit is the industry’s only dedicated meeting for an insider view into which novel approaches are currently being explored\, what benefit each approach has and the directions the space is heading. \nAttendees gain valuable competitive insight into emerging technologies\, early data\, and the rationale behind each approach\, from established pharma leaders to the newest biotech entrants. Whether your goal is to benchmark your pipeline\, explore partnership opportunities\, or stay ahead of fast-moving design trends\, this summit offers a front-row seat to the next wave of conjugate innovation. \nView the program: https://ter.li/m5sjll
URL:http://www.pharmajournalist.com/event/5th-annual-novel-conjugates-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR